有機化学: 現在の研究
オープンアクセス

概要

Synthetic Review of Manufacturing Routes to CDK4/6 Inhibitor Drugs: Palbociclib, Ribociclib and Abemaciclib

Pawan Kumar

Palbociclib, Ribociclib and Abemaciclib are the drugs categorized as CDK4 and CDK6 cyclin-dependent kinase inhibitors. The current article reviews the patent and non-patent journals regarding the synthetic routes and final polymorphic forms of these CDK4/6 inhibitors. Palbociclib (PD0332991, Ibrance^®), Ribociclib (LEE011, Kisqali^®) and Abemaciclib (LY2835219, Bemaciclib, Verzenio^®) are the drugs approved as cyclin-dependent kinase inhibitors (CDK4/6) and are used for the treatment of certain kind of breast cancer. Other reported CDK4/6 inhibitor is Trilaciclib (G1T28) which is still in phase 2 clinical trials. The drug Ribociclib was approved by USFDA on March 13, 2017, Palbociclib was approved by USFDA on March 31, 2017 and Abemaciclib was approved by USFDA on sept.28, 2017.